San Francisco biotech Osanni Bio, looking to build out a suite of ophthalmology- and cardiology-focused
June 23, 2026 02:47 PM EDT
FinancingStartups
Osanni Bio gets $190M to build ophthalmology and cardiology pipeline
Kyle LaHucik
Biotech Correspondent
Ophthalmology venture grabs investors’ attention, raises $330 million
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
[Bio USA] Korean biotechs bolster AstraZeneca partnership
A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.
The trend continues in which big-name venture investors band together to back new companies with an experimental medicine…
Oblenio Bio raises $62M Series B led by Pfizer Venture Investments to advance LBL-051, a trispecific TCE targeting BCMA, CD19,…
Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic.
Ollin Biosciences announced a $330 million Series B to fund pivotal studies around what it hopes can be a more potent competitor…
San Diego's cAMPfield Therapeutics raises $180M Series A backed by Novo Holdings, RA Capital and seven other top-tier life…
